CLINICAL TRIALS PROFILE FOR PILOCARPINE HYDROCHLORIDE

505(b)(2) Clinical Trials for pilocarpine hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02935894 ↗	Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat	Completed	University of California, Davis	N/A	2016-11-28	The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.
OTC	NCT02935894 ↗	Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat	Completed	USDA, Western Human Nutrition Research Center	N/A	2016-11-28	The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.

All Clinical Trials for pilocarpine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003139 ↗	Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1998-03-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
NCT00003139 ↗	Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	1998-03-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
NCT00003686 ↗	Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids	Terminated	NCIC Clinical Trials Group	Phase 3	1998-05-22	RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition. PURPOSE: Randomized phase III trial to determine the effectiveness of pilocarpine in treating patients who have dry mouth caused by opioids.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	CancerCare Manitoba	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Jewish General Hospital	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.

Clinical Trial Conditions for pilocarpine hydrochloride

Condition Name

Condition Name for pilocarpine hydrochloride
Intervention	Trials
Presbyopia	12
Xerostomia	7
Dry Mouth	6
Glaucoma	5

Condition MeSH

Condition MeSH for pilocarpine hydrochloride
Intervention	Trials
Xerostomia	14
Presbyopia	13
Glaucoma	8
Ocular Hypertension	3

Clinical Trial Locations for pilocarpine hydrochloride

Trials by Country

Trials by Country for pilocarpine hydrochloride
Location	Trials
United States	117
Canada	11
China	3
Germany	2
Mexico	2

Trials by US State

Trials by US State for pilocarpine hydrochloride
Location	Trials
California	8
Texas	7
New York	7
Colorado	5
Ohio	5

Clinical Trial Progress for pilocarpine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for pilocarpine hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
Phase 4	6

Clinical Trial Status

Clinical Trial Status for pilocarpine hydrochloride
Clinical Trial Phase	Trials
Completed	26
Recruiting	13
Not yet recruiting	6

Clinical Trial Sponsors for pilocarpine hydrochloride

Sponsor Name

Sponsor Name for pilocarpine hydrochloride
Sponsor	Trials
Roxane Laboratories	4
National Cancer Institute (NCI)	3
Montefiore Medical Center	2

Sponsor Type

Sponsor Type for pilocarpine hydrochloride
Sponsor	Trials
Other	61
Industry	20
NIH	4

Pilocarpine Hydrochloride: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Pilocarpine Hydrochloride remains a critical drug in ophthalmology and dentistry, primarily used to treat glaucoma, ocular hypertension, and xerostomia. Despite its longstanding clinical use, emerging research, evolving regulatory landscapes, and competitor innovations shape its future. This report synthesizes recent clinical trial developments, provides a comprehensive market analysis, and projects industry trends through 2030.

---

Clinical Trials Update

Status of Clinical Research on Pilocarpine Hydrochloride

Recent clinical trials focus on expanding therapeutic indications, improving delivery systems, and assessing safety in new patient populations.

Study ID	Phase	Focus Area	Key Findings	Completion Date	Source
NCT04807522	Phase IV	Ophthalmology	Investigating long-term safety in glaucoma patients	Ongoing	[1], ClinicalTrials.gov
NCT04923765	Phase II	Sjögren’s Syndrome	Evaluating efficacy for xerostomia relief using innovative delivery	2022	[2], ClinicalTrials.gov
NCT05007889	Pilot	Neurodegenerative Disorders	Preliminary safety assessment in Alzheimer’s related dry eyes	2023	[3], ClinicalTrials.gov

Key Insights

• Extended Applications: Trials suggest potential for pilocarpine in neurodegenerative conditions, addressing dry eye symptoms associated with Alzheimer’s disease.
• Formulation Innovations: Research into sustained-release ocular inserts and targeted delivery systems aim to mitigate systemic side effects and improve patient compliance.
• Safety & Tolerability: Long-term safety data continue to support pilocarpine's use in chronic conditions, with ongoing studies monitoring for adverse events such as sweating, gastrointestinal issues, and visual disturbances.

---

Market Analysis

Global Market Size and Growth

Year	Market Value (USD billions)	CAGR (%)	Key Drivers
2022	0.45	3.2	Increased prevalence of glaucoma and xerostomia, aging populations
2023	0.47	3.4	Rising adoption in emerging markets
2025 (Projection)	0.58	5.0	Broader therapeutic indications, technological advances in drug delivery
2030 (Projection)	0.81	7.2	Expansion into neurodegenerative disorder treatments

Source: Market Research Future (2022), GlobalData (2023)

Segment Breakdown

Segment	Market Share (2023)	Key Features	Leading Companies
Ophthalmology	65%	Glaucoma, ocular hypertension	Alcon, Bausch + Lomb, Santen
Dentistry	20%	Xerostomia from radiotherapy/medication	Dexcel Pharma, La Jolla Pharmaceutical
Emerging Use (Neurodegenerative)	5%	Dry eye in Alzheimer’s	Start-up biotech firms
Other	10%	Investigational — using nanotechnology and alternative delivery	Various

Regional Analysis

Region	Market Share (%)	Growth Factors	Challenges
North America	40	Aging demographics, high healthcare expenditure	Patent expirations, generic competition
Europe	25	Healthcare reforms, rising awareness	Regulatory hurdles
Asia-Pacific	20	Growing ophthalmic care, large patient pools	Regulatory variability, pricing pressures
Rest of World	15	Emerging markets, local manufacturing	Infrastructure, market access

---

Competitive Landscape

Company	Product Portfolio	Market Position	R&D Focus	Notable Developments
Alcon	Pilocarpine eye drops, sustained-release implants	Market leader	Delivery systems, biosimilars	Recently licensed a novel ocular insert (2022)
Bausch + Lomb	Pilocarpine formulations	Strong regional presence	Combination therapy	Focus on pediatric formulations (2021)
Santen	Ophthalmic solutions	Expanding in Asia	Biotech integration	Strategic acquisitions in 2023
Start-up Innovators	Nanotech delivery platforms	Niche players	Targeted, minimally invasive delivery	Early-stage trials underway (2023)

Patent Landscape

• Key patents covering sustained-release implants and targeted delivery expire between 2025–2030, generatng opportunities for generics and biosimilars.
• Ongoing patent applications explore nanotechnology-based formulations aimed at reducing systemic absorption.

---

Regulatory Environment & Policy Impact

• FDA (US): Approves ocular and systemic forms, with recent guidance favoring drug-device combination products.
• EMA (Europe): Emphasizes safety in chronic use and encourages innovation in delivery systems.
• Emerging Markets: Regulations vary, with some countries implementing fast-track approvals for ophthalmic solutions addressing unmet needs.
• Intellectual Property: Patent expirations by 2030 facilitate entry of biosimilars and generics, potentially reducing prices.

---

Comparison with Key Alternatives

Drug	Indication	Formulation	Advantages	Limitations
Pilocarpine	Glaucoma, xerostomia	Solution, implant	Well-understood safety profile; low cost	Systemic side effects, compliance issues
Cevimeline	Xerostomia	Oral	Fewer side effects, better compliance	Limited efficacy in glaucoma
Carbachol	Glaucoma	Ophthalmic	Similar mechanism	Higher systemic toxicity risk
New biologics (e.g., Latanoprost)	Glaucoma	Ophthalmic drops	Better tolerability	Costly, less established

---

Future Projections & Industry Trends (2023-2030)

Trend	Expected Impact	Timeline	Stakeholders Affected
Expansion into neurodegenerative disorders	Diversifies use cases	2024–2028	Pharma, biotech, clinicians
Technological innovations in drug delivery	Enhanced patient compliance, reduced systemic effects	2023–2030	R&D firms, clinicians
Increasing generic and biosimilar competition	Price reduction, market saturation	2025–2030	Manufacturers, payers
Personalized medicine approaches	Targeted treatments, improved outcomes	2024–2030	R&D, policy regulators

---

Key Takeaways

• Clinical trials are increasingly exploring novel delivery systems and expanded indications, particularly for neurodegenerative-related dry eye.
• The global market is expected to grow at a CAGR of approximately 6.3% through 2030, driven by aging populations and technological advances.
• Patent expirations from 2025 onward will facilitate market entry of biosimilars and generics, pressuring prices.
• Major players focus on innovative formulations and targeted delivery, with emerging biotech firms exploring nanotech solutions.
• Regulatory environments globally continue to favor innovation with streamlined approval pathways, especially in emerging markets.

---

FAQs

1. What are the primary therapeutic indications for Pilocarpine Hydrochloride?
Clinically approved for glaucoma, ocular hypertension, and xerostomia, particularly in Sjögren’s syndrome and post-radiation therapy patients.

2. How is the market for Pilocarpine Hydrochloride expected to evolve over the next decade?
The market is projected to grow at a CAGR of 6.3%, reaching approximately USD 810 million by 2030, driven by expanded indications, technological advancements, and aging demographics.

3. What are promising areas of clinical research concerning Pilocarpine?
Research is focusing on formulation innovations like sustained-release implants, targeted delivery, and exploring efficacy in neurodegenerative diseases with dry eye symptoms.

4. Who are the key competitors in the Pilocarpine Hydrochloride market?
Alcon, Bausch + Lomb, Santen, and biotech startups focusing on nanotechnology-enabled delivery systems.

5. What regulatory challenges could impact the future of Pilocarpine Hydrochloride?
Patent expirations may lead to generic entry, impacting pricing. Additionally, regulatory focus on safety in chronic use necessitates robust long-term safety data.

---

References

[1] ClinicalTrials.gov, NCT04807522. "Long-term Safety of Pilocarpine in Glaucoma," 2022.
[2] ClinicalTrials.gov, NCT04923765. "Efficacy of Novel Delivery Systems for Sjögren’s Syndrome," 2022.
[3] ClinicalTrials.gov, NCT05007889. "Pilocarpine Safety in Neurodegenerative Disorders," 2023.
[4] Market Research Future reports, 2022. "Global Ophthalmic Drugs Market."
[5] GlobalData, 2023. "Ophthalmic Drugs Market Analysis."